Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
41 hedge funds and large institutions have $18.6M invested in Elevation Oncology in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 5 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
5% more funds holding
Funds holding: 39 → 41 (+2)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
61% less capital invested
Capital invested by funds: $47.9M → $18.6M (-$29.4M)
63.38% less ownership
Funds ownership: 129.57% → 66.18% (-63%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$724K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$156K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$110K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$95K |
| 5 |
Two Sigma Advisers
New York
|
+$77.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.1M |
| 2 |
AC
Armistice Capital
New York
|
-$1.66M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.26M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$608K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$505K |
ELEV Hedge Fund Activity: Q3 2023 in Review
41 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q3 2023, worth a combined $18.6M — down 61% from $47.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ELEV positions and 5 closed out — a net gain of 2 holders — while 13 added to existing stakes and 7 trimmed.
The largest buyer was Millennium Management, adding an estimated $724K. The largest seller was Deerfield Management, exiting entirely with an estimated $2.1M sold.
- 41 institutional investors held Elevation Oncology (ELEV) as of Q3 2023, up from 39 in Q2 2023.
- Funds reported $18.6M of Elevation Oncology stock for Q3 2023, down 61% quarter-over-quarter.
- 7 funds opened new Elevation Oncology positions in Q3 2023 and 5 closed out, a net change of +2 holders.
- The largest Elevation Oncology buyer in Q3 2023 was Millennium Management, an estimated $724K added.
- The largest Elevation Oncology seller in Q3 2023 was Deerfield Management, an estimated $2.1M sold.
Based on aggregated 13F filings for Q3 2023.